Search results for "SUBSTITUTION"

showing 10 items of 536 documents

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone

2021

International audience; Aim: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France.Methods: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-re…

MaleNarcotic Antagonists[SDV]Life Sciences [q-bio]ToxicologyMESH: Analgesics Opioid0302 clinical medicineInterquartile rangeSurveys and QuestionnairesPharmacology (medical)030212 general & internal medicineSurveymedia_commonMESH: Patient PreferenceMESH: Middle AgedOpioid use disorderPatient PreferenceMiddle AgedBuprenorphineAnalgesics OpioidPsychiatry and Mental healthMESH: Young AdultFemaleFranceMESH: Narcotic AntagonistsPatients' preferencemedicine.drugAdultmedicine.medical_specialtyAdolescentMESH: Delayed-Action Preparationsmedia_common.quotation_subjectMESH: BuprenorphineMESH: Opiate Substitution TreatmentInjections03 medical and health sciencesYoung AdultInternal medicinemedicineOpiate Substitution TreatmentHumansMESH: InjectionsDosingMESH: Surveys and QuestionnairesPharmacologyMESH: AdolescentMESH: Humansbusiness.industryMESH: AdultOdds ratioAbstinencemedicine.diseaseOpioid-Related DisordersConfidence intervalMESH: MaleMESH: Opioid-Related DisordersMESH: FranceDelayed-Action PreparationsMESH: MethadoneExtended-releasebusinessMESH: Female030217 neurology & neurosurgeryMethadoneMethadoneBuprenorphine
researchProduct

Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL–C levels in a latvi…

2015

Background Familial hypercholesterolemia (FH) is one of the commonest monogenic disorders, predominantly inherited as an autosomal dominant trait. When untreated, it results in early coronary heart disease. The vast majority of FH remains undiagnosed in Latvia. The identification and early treatment of affected individuals remain a challenge worldwide. Most cases of FH are caused by mutations in one of four genes, APOB, LDLR, PCSK9, or LDLRAP1. The spectrum of disease-causing variants is very diverse and the variation detection panels usually used in its diagnosis cover only a minority of the disease-causing gene variants. However, DNA-based tests may provide an FH diagnosis for FH patients…

MaleNonsynonymous substitutionApolipoprotein BCoronary Artery DiseaseFamilial hypercholesterolemiaDiseaseCohort StudiesPCSK9Genetics(clinical)Family historyGenetics (clinical)Aged 80 and overGeneticseducation.field_of_studybiologySerine EndopeptidasesHigh-Throughput Nucleotide SequencingAutosomal dominant traitMiddle AgedLDLRAP1Apolipoprotein B-100Femalelipids (amino acids peptides and proteins)Proprotein ConvertasesProprotein Convertase 9APOBResearch ArticleAdultPopulationPolymorphism Single NucleotideLDLHyperlipoproteinemia Type IIYoung AdultGeneticsmedicineHumanseducationAdaptor Proteins Signal TransducingAgedDiagnostic toolsPCSK9Cholesterol LDLmedicine.diseaseLatviaGenetics PopulationLDLRReceptors LDLMutationNext-generation sequencingbiology.proteinBMC Medical Genetics
researchProduct

A second family with familial AD and the V717L APP mutation has a later age at onset

2006

Four mutations have been reported at the 717 codon of the amyloid precursor protein (APP), with valine substituted by isoleucine, glycine, phenylalanine, and leucine. While several families with the isoleucine substitution have been described, the other substitutions have been reported in only one family each worldwide. A family with the V717L APP mutation has been previously reported,1 with a mean age at onset of 38 years (range 35 to 39), based on four affected family members, and a mean age at death of 46 years (range 40 to 50). We have identified a second family with a later mean age at onset of 50 years (range 48 to 57) and mean age at death of 61 years (range 57 to 68). Family 171 is …

MalePediatricsmedicine.medical_specialtyMutation Missensemedicine.disease_causeAmyloid beta-Protein PrecursorAlzheimer DiseaseValineInternal medicinemedicineAmyloid precursor proteinHumansAge of OnsetAgedAge of Onset Aged Alzheimer Disease/genetics Alzheimer Disease/physiopathology Amino Acid Substitution Amyloid beta-Protein Precursor/genetics Female Humans Malle Middle Aged Mutation Missense PedigreeMutationSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicabiologyMean ageMiddle AgedPedigreeEndocrinologyAmino Acid Substitutionbiology.proteinFemaleNeurology (clinical)IsoleucineNeurology
researchProduct

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

2008

Abstract Objective: To analyse the effect of hydroxyurea (HU) on the JAK2-V617F allelic ratio (%JAK2-V617F) of patients with Polycythaemia Vera (PV) and Essential Thrombocythaemia (ET). Methods: Thirty-six patients were examined sequentially prior to and after on-set of (HU) therapy (8 PV, 17 ET), or while remaining untreated (2 PV, 9 ET). For all patients, the %JAK2-V617F was determined in purified blood granulocytes using sensitive allele-specific, quantitative PCRs. In a second study, two distinct groups of patients were examined at a single time point at the time of diagnosis (99 PV, 178 ET) or while receiving HU (36 PV, 98 ET). Results: HU therapy (median duration: 15 months) reduced t…

MalePediatricsmedicine.medical_specialtymedicine.drug_classImmunologyClone (cell biology)Allelic ratioBiochemistryAntimetaboliteGastroenterologyCohort StudiesHydroxycarbamidePolycythemia veraAntisickling Agentshemic and lymphatic diseasesInternal medicinemedicineHumansHydroxyureaProspective cohort studyPolycythemia VeraMyeloproliferative neoplasmAgedDNA PrimersRetrospective StudiesAged 80 and overJanus kinase 2HematologybiologyEssential thrombocythemiabusiness.industryCell BiologyHematologyJanus Kinase 2Middle Agedmedicine.diseaseSurgeryAmino Acid SubstitutionMutationbiology.proteinFemalebusinessGranulocytesThrombocythemia Essentialmedicine.drugHaematologica
researchProduct

Sexual size dimorphism predicts rates of sequence evolution of SPerm Adhesion Molecule 1 (SPAM1, also PH-20) in monkeys, but not in hominoids (apes i…

2010

Based on a dataset comprising coding DNA sequences of 23 anthropoid primates, we herein investigate if rates of sequence evolution of SPerm Adhesion Molecule 1 (SPAM1, also PH-20), which participates in sperm–egg interaction, is lower in more sexually dimorphic species. For comparison, we analyze sequence evolution of apolipoprotein A-IV (APOA4) and apolipoprotein A-V (APOA5), which should evolve under less or even no sexual selection given their expression in blood, digestive tract, liver, and lungs. Regression analyses provides significant support for a negative dependence of SPAM1 derived branch-specific ratios of non-synonymous to synonymous substitution rates (dN/dS) on sexual size dim…

MalePrimatesDNA ComplementaryOld WorldHyaluronoglucosaminidaseBiologyEvolution MolecularTestisGeneticsAnimalsMolecular BiologySperm competitionApolipoproteins AEcology Evolution Behavior and SystematicsGeneticsLikelihood FunctionsSex CharacteristicsModels GeneticConfoundingOrgan SizeSequence Analysis DNAMating systemSexual dimorphismMate choiceSexual selectionRegression AnalysisFemaleSynonymous substitutionCell Adhesion MoleculesMolecular Phylogenetics and Evolution
researchProduct

New Hyperekplexia Mutations Provide Insight into Glycine Receptor Assembly, Trafficking, and Activation Mechanisms*

2013

Hyperekplexia is a syndrome of readily provoked startle responses, alongside episodic and generalized hypertonia, that presents within the first month of life. Inhibitory glycine receptors are pentameric ligand-gated ion channels with a definitive and clinically well stratified linkage to hyperekplexia. Most hyperekplexia cases are caused by mutations in the α1 subunit of the human glycine receptor (hGlyR) gene (GLRA1). Here we analyzed 68 new unrelated hyperekplexia probands for GLRA1 mutations and identified 19 mutations, of which 9 were novel. Electrophysiological analysis demonstrated that the dominant mutations p.Q226E, p.V280M, and p.R414H induced spontaneous channel activity, indicat…

MaleProtein subunitMutation MissenseBiologyBiochemistryProtein Structure SecondaryReceptors GlycinemedicineHumansHyperekplexiaReceptorMolecular BiologyGlycine receptorIon channelGeneticsWild typeMolecular Bases of DiseaseCell BiologyMuscle RigidityProtein Structure TertiaryAmino Acid SubstitutionGene Expression RegulationFemalemedicine.symptomIon channel linked receptorsCys-loop receptors
researchProduct

Molecular Basis of Hereditary C1q Deficiency

1998

Abstract Complete selective deficiencies of the complement component C1q are rare genetic disorders which are associated with recurrent infections and a high prevalence of lupus erythematosus-like symptoms. The improvements in molecular biology techniques have facilitated the analysis of such genetic defects to a great extend. To date the basis of C1q deficiencies from 13 families have been studied at the genetic level. In each case single base mutations leading to either termination codons, frame shift or amino acid exchanges were thought to be responsible for these defects as no other aberrations were found. In addition to DNA analysis, conventional immunochemical and biochemical methods …

MaleRecurrent infectionsGenotypeTurkeyImmunologySaudi ArabiaBiologyAutoimmune DiseasesFrameshift mutationchemistry.chemical_compoundC1q DeficiencyGermanyComplement component C1qmedicineHumansLupus Erythematosus SystemicPoint MutationImmunology and AllergyGenetic Predisposition to DiseaseSequence DeletionGeneticsSystemic lupus erythematosusComplement C1qImmunologic Deficiency SyndromesHematologymedicine.diseaseStructure and functionAmino Acid SubstitutionchemistryChromosomes Human Pair 1Codon NonsenseFemaleDNAImmunobiology
researchProduct

Changes of QTc interval after opioid switching to oral methadone.

2013

Abstract A consecutive sample of patients who were switched from strong opioids to methadone in a period of 1 year was surveyed. QTc was assessed before switching (T0) and after achieving adequate analgesia and an acceptable level of adverse effects (Ts). Twenty-eight of 33 patients were switched to methadone successfully. The mean initial methadone doses at T0 were 67.1 mg/day (SD ±80.2, range 12-390). The mean QTc interval at T0 was 400 ms (SD ±30, range 330-450). The mean QTc interval at Ts (median 5 days) was 430 ms (SD ±26, range 390-500). The difference (7.7 %) was significant (p < 0.0005). Only two patients had a QTc of 500 ms. No serious arrhythmia was observed. At the linear regres…

MaleRiskCancer pain; Methadone; QT prolongation; Toxicity; Opioid switchingPainSettore MED/41 - AnestesiologiaQT prolongationSettore MED/42 - Igiene Generale E ApplicataQT intervalCONSECUTIVE SAMPLEElectrocardiographyNeoplasmsOpiate Substitution TreatmentmedicineHumansIn patientcardiovascular diseasesCancer painAdverse effectAgedToxicitybusiness.industryMiddle AgedAnalgesics OpioidLong QT SyndromeOncologyOpioidAnesthesiaToxicityLinear Modelscardiovascular systemOpioid switchingFemaleCancer painbusinessMethadoneMethadonemedicine.drug
researchProduct

Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syn…

2011

Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart disease risk factors. This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk hypercholesterolaemic patients with ( n=368) and without ( n=217) MetS who had previously been on statin monotherapy. Patients were randomised 1:1 to double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks. Least squares mean percent change from baseline and 95% confidence intervals in lipid efficacy parameters were calculated for the population and within subgroups. Treatment with ezetimibe/simvastatin was significantly more effect…

MaleSimvastatinSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismEzetimibe Simvastatin Drug CombinationCoronary DiseaseGastroenterologychemistry.chemical_compoundRisk FactorsDrug CombinationAzetidineAnticholesteremic AgentOdds RatioRosuvastatin CalciumMetabolic Syndromeeducation.field_of_studySulfonamidesDrug SubstitutionMetabolic Syndrome XAnticholesteremic AgentsLipidMiddle AgedLipidsEuropeRosuvastatin CalciumDrug CombinationsCholesterolTreatment Outcomelipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular Medicinemedicine.drugHumanmedicine.medical_specialtyStatinLogistic Modelmedicine.drug_classPopulationHypercholesterolemiaSulfonamideRisk AssessmentEzetimibeDouble-Blind MethodInternal medicineInternal MedicinemedicineHumansRosuvastatinLeast-Squares AnalysiseducationAgedApolipoproteins BLeast-Squares AnalysiAnalysis of VarianceCholesterolbusiness.industryRisk FactorFluorobenzenenutritional and metabolic diseasesCholesterol LDLFluorobenzenesEndocrinologyLogistic ModelsPyrimidineschemistryPyrimidineSimvastatinBiological MarkerAzetidinesEzetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersDiabetesvascular disease research
researchProduct

Mutations in the PDS Gene in German Families with Pendred’s Syndrome: V138F Is a Founder Mutation

2003

Pendred's syndrome, an autosomal-recessive condition characterized by congenital sensorineural hearing loss and goiter, is caused by mutations in the PDS gene. Located on chromosome 7q22-q31, it encodes a chloride-iodide transporter expressed in the thyroid, inner ear, and kidney. We investigated the PDS gene of six affected individuals from four unrelated families with Pendred's syndrome by direct sequencing. PDS mutations were identified in homozygous or compound heterozygous state in all six cases. A homozygous missense mutation leading to the amino acid substitution S133T was detected in a family of Turkish origin. The mutations found in the other affected individuals, who originate fro…

MaleThreoninemedicine.medical_specialtyAdolescentTurkeyHearing Loss SensorineuralEndocrinology Diabetes and MetabolismClinical BiochemistryMutation MissenseBiologyCompound heterozygositymedicine.disease_causeBiochemistryGenetic determinismEndocrinologyHypothyroidismGermanyInternal medicineSerinemedicineHumansMissense mutationAlleleChildPendred syndromeGeneticsMutationBase SequenceBiochemistry (medical)HaplotypeInfant NewbornMembrane Transport Proteinsfood and beveragesSyndromemedicine.diseaseFounder EffectPedigreeEndocrinologyAmino Acid SubstitutionHaplotypesSulfate TransportersChild PreschoolMicrosatelliteFemaleCarrier ProteinsThe Journal of Clinical Endocrinology &amp; Metabolism
researchProduct